Office: 306 Pavilion
Wen Xie (MD, PhD) is Professor of Pharmaceutical Sciences and Pharmacology, Interim Chair of the Department of Pharmaceutical Sciences, Director of the Center for Pharmacogenetics, and Joseph Koslow Endowed Chair in Pharmaceutical Sciences.
Dr. Xie obtained his MD degree from Peking University Health Science Center, and PhD in Cell Biology from University of Alabama at Birmingham. He completed a postdoctoral fellowship with Dr. Ronald M. Evans at the Salk Institute in La Jolla, California before joining the University of Pittsburgh in 2002. Dr. Xie holds a secondary appointment at the Department of Pharmacology and Chemical Biology at the School of Medicine.
The research focus of Dr. Xie's laboratory is nuclear receptor-mediated transcriptional regulation of genes that encode drug metabolizing enzymes and drug transporters. In addition to metabolizing drugs, the same enzyme and transporter systems are also responsible for the homeostasis of numerous endobiotic molecules. Therefore, this regulation has broad implications in drug metabolism and many human diseases, including hepatobiliary diseases, endocrine disorders, metabolic syndrome, and cancers. Dr. Xie’s research is conducted using a combination of cell cultures and genetically engineered mice that include transgenic, knockout and humanized mice.
Dr. Xie is the author or coauthor of more than 170 journal articles and book chapters and he has delivered over 180 invited lectures at conferences and universities. Dr. Xie has edited two books: "Nuclear Receptors in Drug Metabolism", a book published by Wiley in 2008 and "Drug Metabolism in Diseases", an Elsevier book published in 2016. Dr. Xie has served as ad hoc reviewer for NIH and DOD Study Sections and for over 90 scientific journals.
Among his achievements, Dr. Xie is the recipient of the University of Pittsburgh Chancellor’s Distinguished Research Award (2008), the James R. Gillette International Society for the Study of Xenobiotics (ISSX) North American New Investigator Award (2008), the American Society for Pharmacology and Experimental Therapeutics (ASPET) Division for Drug Metabolism Early Career Achievement Award (2009), and the Joseph Koslow Endowed Chair in Pharmaceutical Sciences (2012).
Orphan nuclear receptor-mediated gene regulation in drug metabolism and human diseases.
Selected publications since 2012:
Gao J, He J, Shi X, Stefanovic-Racic M, Xu M, O'Doherty RM, Garcia-Ocana A, Xie W. Sex-specific effect of estrogen sulfotransferase (EST) on mouse models of type 2 diabetes. Diabetes 61: 1543-1551 (2012) PMID: 22438574
Gao J, Xie W. Targeting xenobiotic receptors PXR and CAR for metabolic diseases. Trends Pharmacol Sci. 33: 552-558 (2012) PMID: 22889594
Ou Z, Shi X, Gilroy RK, Kirisci L, Romkes M, Lynch C, Wang H, Xu M, Jiang M, Ren S, Gramignoli R, Strom SC, Huang M, Xie W. Regulation of the human hydroxysteroid sulfotransferase SULT2A1 by ROR alpha and ROR gamma and its potential relevance in human liver diseases. Mol Endocrinol 27: 106-115 (2013) PMID: 23211525
Jiang M, Xie W. Role of the constitutive androstane receptor in obesity and type 2 diabetes, a case study of the endobiotic function of a xenobiotic receptor. Drug Metab Rev. 45: 156-163 (2013) PMID: 23330547
Chai X, Zeng S, Xie W. Nuclear receptors PXR and CAR: implications for drug metabolism regulation, pharmacogenomics and beyond. Expert Opin Drug Metab Toxicol. 9: 253-266 (2013) PMID: 23327618
He J, Gao J, Xu M, Ren S, Stefanovic-Racic M, O'Doherty RM, Xie W. PXR ablation alleviates diet-induced and genetic obesity and insulin resistance in mice. Diabetes 62: 1876-1887 (2013) PMID: 23349477.
He J, Hu B, Shi X, Weidert ER, Lu P, Xu M, Huang M, Kelley EE, Xie W. Activation of the aryl hydrocarbon receptor sensitizes mice to non-alcoholic steatohepatitis by deactivating the mitochondrial sirtuin deacetylase Sirt3. Mol Cell Biol 33: 2047-2055 (2013) PMID: 23508103
Kittayaruksakul S, Zhao W, Xu M, Ren S, Lu J, Wang J, Downes M, Evans RM, Venkataramanan R, Chatsudthipong V, Xie W. Identification of three novel natural product compounds that activate PXR and CAR and inhibit inflammation. Pharm Res 30: 2199-2208 (2013) PMID: 23896737
Shi X, Cheng Q, Xu L, Yan J, Jiang M, He J, Xu M, Stefanovic-Racic M, Sipula I, O'Doherty RM, Ren S, Xie W. Cholesterol Sulfate and Cholesterol Sulfotransferase Inhibit Gluconeogenesis by Targeting HNF4α. Mol Cell Biol. 34: 485-497 (2014) PMID: 24277929
Jiang M, He J, Kucera H, Gaikwad N, Zhang B, Xu MW, O'Doherty RM, Selcer KW, Xie W. Hepatic over-expression of steroid sulfatase ameliorates mouse models of obesity and type 2 diabetes through sex-specific mechanisms. J Biol Chem. 289: 8086-8097 (2014) PMID: 24497646
Ihunnah CA, Wada T, Philips BJ, Ravuri SK, Gibbs RB, Kirisci L, Rubin JP, Marra KG, Xie W. Estrogen sulfotransferase (EST/SULT1E1) promotes human adipogenesis. Mol Cell Biol 34: 1682-1694 (2014) PMID: 24567372
Ou Z, Jiang M, Hu B, Huang Y, Xu M, Ren S, Li S, Liu S, Xie W, Huang M. Transcriptional Regulation of Human Hydroxysteroid Sulfotransferase SULT2A1 by LXR. Drug Metab Dispos. 42: 1684-1689 (2014). PMID: 25028566
Lu P, Yan J, Liu K, Garbacz WG, Wang P, Xu M, Ma X, Xie W. Activation of Aryl Hydrocarbon Receptor Dissociates Fatty Liver from Insulin Resistance by Inducing FGF21. Hepatology 61: 1908-1919 (2015) PMID: 25614121
Cheng Q, Inaba Y, Lu P, Xu M, He J, Zhao Y, Guo GL, Kuruba R, De La Vega R, Evans RW, Li S, Xie W. Chronic activation of FXR in transgenic mice caused perinatal toxicity and sensitized mice to cholesterol toxicity. Mol Endocrinol 29: 571-582 (2015) PMID: 25719402
Guo Y, Hu B, Huang H, Tsung A, Gaikwad N, Xu M, Jiang M, Ren S, Fan J, Billiar TR, Huang M, Xie W. Estrogen sulfotransferase is an oxidative stress responsive gene that gender-specifically affects liver ischemia/reperfusion injury. J Biol Chem. 290: 14754-14764 (2015) PMID: 25922074
Hu B, Guo Y, Garbacz WG, Jiang M, Xu M, Huang H, Tsung A, Billiar TR, Ramakrishnan SK, Shah YM, Lam KSL, Huang M, Xie W. Fatty acid binding protein-4 (FABP4) is a hypoxia inducible gene that sensitizes mice to liver ischemia/re-perfusion injury. J Hepatol 63: 855-862 (2015) PMID: 26070408
Lu P, Xie W. Reply to Correspondence HEP-15-1008 “AHR-FGF21 dissociation of fatty liver from insulin resistance: a timely matter?” Hepatology 63: 1397-1398 (2016) PMID: 26109100
Chai X, Guo Y, Jiang M, Hu B, Li Z, Fan J, Deng M, Billiar TR, Kucera H, Gaikwad NW, Xu M, Lu P, Yan J, Fu H, Liu Y, Yu L, Huang M, Zeng S, Xie W. Estrogen sulfotransferase ablation sensitizes mice to sepsis. Nat Commun. 6: 7979 (2015) PMID: 26259151
Jiang M, Klein M, Zanger UM, Mohammad MK, Cave MC, Gaikwad NW, Dias NJ, Selcer KW, Guo Y, He J, Zhang X, Shen Q, Qin W, Li J, Li S, Xie W. Inflammatory regulation of steroid sulfatase, a novel mechanism to control estrogen homeostasis and inflammation in chronic liver disease. J Hepatol. 2016; 64: 44-52 PMID: 26220752
Gao J, Yan J, Xu M, Ren S, Xie W. CAR suppresses hepatic gluconeogenesis by facilitating the ubiquitination and degradation of PGC1α. Mol Endocrinol 29: 1558-1570 (2015) PMID: 26407237
Guo Y, Hu B, Xie Y, Billiar TR, Sperry JL, Huang M, Xie W. Regulation of drug-metabolizing enzymes by local and systemic liver injuries Expert Opin Drug Metab Toxicol. 12: 245-51 (2016) PMID: 26751558
Zhao Z, Xu D, Li S, He B, Huang Y, Xu M, Ren S, Li S, Wang H, Xie W. Activation of liver X receptor attenuates oleic acid-induced acute respiratory distress syndrome. Am J Pathol. 186: 2614-2622 (2016) PMID: 27520356
Garbacz WG, Lu P, Miller TM, Poloyac SM, Eyre NS, Mayrhofer G, Xu M, Ren S, Xie W. Hepatic overexpression of CD36 improves glycogen homeostasis and attenuates high-fat diet induced hepatic steatosis and insulin resistance. Mol Cell Biol. 36: 2715-2727 (2016) PMID: 27528620
Chen Y, Xia R, Huang Y, Zhao W, Li J, Zhang X, Wang P, Venkataramanan R, Fan J, Xie W, Ma X, Lu B, Li S. An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy. Nat Commun 7: 13443 (2016). PMID: 27819653
Niu Y, Xu M, Slagle BL, Huang H, Li S, Guo GL, Shi G, Qin W, Xie W. Farnesoid X receptor (FXR) ablation sensitizes mice to hepatitis B virus X protein (HBx)-induced hepatocarcinogenesis. Hepatology 65: 893-906 (2017) PMID: 28102638
Hu B, Li Y, Gao L, Guo Y, Zhang Y, Chai X, Xu M, Yan J, Lu P, Ren S, Zeng S, Liu Y, Xie W¶, Huang M¶. Hepatic induction of fatty acid binding protein 4 (FABP4) plays a pathogenic role in sepsis in mice. Am J Pathol 187: 1059-1067 (2017) PMID: 28279656 (¶, co-corresponding authors)
Zheng Z, Zhao Z, Li S, Lu X, Jiang M, Lin J, An Y, Xie Y, Xu M, Shen W, Guo GL, Huang Y, Li S, Zhang X, Xie W. Altenusin, a non-steroidal microbial metabolite, attenuates non-alcoholic fatty liver disease by activating the farnesoid X receptor. Mol Pharmacol 2017 Jul 24 [Epub ahead of print] PMID: 28739572
Garbacz WG, Jiang M, Xu M, Yamauchi J, Dong HH, Xie W. Sex- and tissue-specific role of estrogen sulfotransferase in energy homeostasis and insulin sensitivity. Endocrinology (Accepted)
University of Pittsburgh Chancellor’s Distinguished Research Award (2008)
The James R. Gillette International Society for the Study of Xenobiotics (ISSX) North American New Investigator Award (2008)
The American Society for Pharmacology and Experimental Therapeutics (ASPET) Division for Drug Metabolism Early Career Achievement Award (2009)
The Joseph Koslow Endowed Chair in Pharmaceutical Sciences (2012)
Selected presentations since 2013 (outside University of Pittsburgh):
The Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland. Baltimore, Maryland. April 10, 2013
School of Basic Medical Sciences, Capital Medical University, Beijing, China. June 4, 2013.
Department of Pharmaceutical Analysis and Drug Metabolism, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, China. June 5, 2013
10th International ISSX Meeting. Toronto, Ontario, Canada. September 29-October 3, 2013
2013 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting. San Antonio, Texas. November 10-14, 2013.
School of Pharmacy, The Chinese University of Hong Kong. Hong Kong, China. December 5, 2013
1st Ling-Nan International DMPK Summit Conference. Guangzhou, China. December 5-8, 2013
10th Biennial Meeting of Chinese Biological Investigators Society (CBIS), Cancun, Mexico. December 21-24, 2013
53rd Society of Toxicology Annual Meeting, Phoenix, AZ. March 23-27, 2014.
20th Microsomes and Drug Oxidations (MDO) Meeting. Stuttgart, Germany. May 18-22, 2014.
6th Forum on Intestinal Barriers and Related Diseases. Beijing, China. June 6-8, 2014.
Sino-U.S. Forum on Infectious Diseases and Liver Diseases, Beijing 302 Hospital. Beijing, China. June 9, 2014.
Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’An, China. June 13, 2014.
College of Life Science, Beijing Normal University. Beijing, China. June 18, 2014.
NIEHS Tamburro Liver Symposium (Symposium on Environmental Liver Disease). Louisville, Kentucky. September 11-12, 2014.
Departments of Environmental Medicine & Pharmacology, New York University Langone Medical Center. Tuxedo, NY. November 7, 2014.
Department of Microbiology and Immunology, School of Medicine, Virginia Commonwealth University. Richmond, Virginia. November 11, 2014
Department of Biological Sciences, Duquesne University, Pittsburgh, PA. February 6, 2015.
Experimental Biology 2014 Meeting/ASPET, Boston, MA. March 28-April 1, 2015.
Department of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai, China. April 10, 2015.
1st Sunrise Symposium for Drug Metabolism, Pharmacokinetics and Dynamics, Nanjing, China. April 11-13, 2015.
Annual Meeting of the Canadian Society of Pharmaceutical Sciences (CSPS), Toronto, Ontario, May 26-29, 2015
School of Pharmaceutical Sciences, Anhui Medical University. Hefei, China. August 19, 2015.
Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan. October 28, 2015.
UC Davis Cancer Center, Sacramento, CA. November 12, 2015.
Department of Cancer Biology, the Lerner Research Institute of the Cleveland Clinic. Cleveland, Ohio. November 24, 2015.
2nd Ling-Nan International DMPK Summit Conference. Guangzhou, China. December 4-6, 2015.
Department of Pharmacology, College of Pharmacy and Pharmaceutical Sciences, University of Toledo. Toledo, Ohio. March 23, 2016.
School of Pharmaceutical Sciences, Peking University Health Science Center. Beijing, China. June 3, 2016.
Department of Biology, South University of Science and Technology of China. Shenzhen, China. June 6, 2016.
11th Biennial Meeting of Chinese Biological Investigators Society (CBIS), Chengdu, China. July 29-August 2, 2016.
Center for Molecular Toxicology and Carcinogenesis, Penn State University, University Park, PA. September 14, 2016
21th Microsomes and Drug Oxidations (MDO) Meeting (Speaker and Session Chair). Davis, CA. October 2-6, 2016.
2016 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting. Denver, Colorado. November 13-17, 2016.
Guangdong Provincial Key Laboratory of Liver Disease, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. December 8, 2016.
School of Pharmaceutical Sciences, Sun Yat-Sen University. Guangzhou, China. December 8, 2016.
2st Sunrise Symposium for Drug Metabolism, Pharmacokinetics and Dynamics, Xiamen, China. December 9-11, 2016.
School of Basic Medical Sciences, Capital Medical University, Beijing, China. December 14, 2016.
Department of Departments of Biopharmaceutical Sciences, University of Illinois at Chicago College of Pharmacy, Chicago, IL. March 7, 2017.
Gordon Research Conference on Drug Metabolism. Holderness School, Plymouth, New Hampshire. July 9-14. 2017
Department of Hepatology and Gastroenterology, the First Affiliated Hospital of Norman Bethune College of Medicine, Jilin University, Jilin, China. August 1, 2017.
Shenyang DMPK Workshop, Shenyang Pharmaceutical University, Shenyang, Liaoning, China. August 2-4, 2017.
Gordon Research Conference on Cellular & Molecular Mechanisms of Toxicology (Speaker and Session Chair). Proctor Academy, Andover, NH, August 13-18, 2017.
2017 American Association for The Study of Liver Diseases (AASLD) Meeting, Washington DC. October 20-24, 2017